Bootstrapped · Biotech · Stockholm, Sweden · Founded 2018 · 11–50 employees
Oxcia is a clinical-stage biotech company developing innovative therapies targeting oxidative stress and DNA damage response to treat cancer and inflammatory diseases. Their lead candidate OXC-101 is a first-in-class mitotic MTH1 inhibitor in Phase I/II trials for acute myeloid leukemia with FDA orphan drug designation. Their second asset OXC-201 is a novel OGG1 inhibitor being developed for idiopathic pulmonary fibrosis. The company received a €2.5 million EIC Transition grant in 2023, making it the only Swedish company to receive this prestigious European funding in that call. Oxcia has built a unique O2-DDR technology platform with potential applications across multiple disease areas including cancer, inflammation, and fibrosis.
No open roles listed right now.